Sorrento Developed Socazolimab Enters Late-Stage Lung Cancer Study In China

China's regulatory authorities have signed off on Lee's Pharmaceutical Holdings Limited's Phase 3 trial evaluating socazolimab in small-cell lung cancer.

• Lee Pharma has in-licensed socazolimab from Sorrento Therapeutics Inc (NASDAQ: SRNE) for the greater China territory.
• The multicenter, randomized, double-blinded, parallel-group trial will combine socazolimab with chemotherapy in the first-line treatment of extensive-stage small-cell lung cancer.
• The clearance is based on the results from an earlier Phase 1b trial in which socazolimab combined with carboplatin and etoposide showed a promising efficacy and safety profile.
• Patient recruitment will start in the second quarter of 2021.
• Socazolimab is a fully human anti-PD-L1 monoclonal antibody identified by Sorrento using its proprietary G-MAB library platform.
• Price Action: SRNE shares are trading 3.7% higher at $9.21 in the premarket session on the last check Monday.